Amneal Expands Iohexol Injection Portfolio with FDA Approvals — Amneal Pharmaceuticals, Inc.

Event summary

Amneal received FDA approval for additional strengths and vial presentations of iohexol injection, including 350 mg iodine/mL in 50 mL, 75 mL, and 100 mL vials, and 300 mg iodine/mL in a 50 mL vial.
The approvals position Amneal to address the majority of U.S. market demand for iohexol injection.
Amneal plans to launch these products in Q3 2026.
IQVIA® reported U.S. annual sales for iohexol injection at approximately $706 million for the 12 months ended May 2026.

The big picture

Amneal's FDA approvals for additional iohexol injection strengths and presentations strengthen its position in the U.S. market for radiographic contrast agents. The move aligns with broader industry trends toward generic alternatives to branded products, potentially driving cost savings for hospitals and imaging centers. With annual sales of iohexol injection nearing $706 million, Amneal's expanded portfolio could significantly boost its revenue and market share in the injectables segment.

What we're watching

Market Penetration: How Amneal will leverage its expanded iohexol portfolio to capture a larger share of the $706 million U.S. market.
Execution Risk: The pace at which Amneal can successfully launch and distribute the new iohexol presentations in Q3 2026.
Competitive Dynamics: Whether Amneal can sustain its leadership position in complex injectables amid competition from branded products like OMNIPAQUE™.